Skip to main content
Erschienen in: CardioVasc 6/2012

20.12.2012 | Pro & Kontra

Einfache Therapie fördert die Compliance

„Fire and forget“ statt „Treat to target“

verfasst von: Prof. Dr. med. Bernd Mühlbauer

Erschienen in: CardioVasc | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten
Literatur
  1. Bauchner H, Fontanarosa B The Debut of Dueling Viewpoints JAMA. 2012;307(14):1532–1532PubMedView Article
  2. Redberg RF, Katz MH Healthy Men Should Not Take Statins JAMA. 2012;307(14):1491–1492PubMedView Article
  3. Blaha J et al. Therapy for Healthy Men Identified as „Increased Risk“ JAMA. 2012;307(14):1489–1490PubMedView Article
  4. Beckman JA, Use of Statins in Healthy Men, JAMA 2012;308(7):666PubMedView Article
  5. Heart Protection Study Collaborative Group, Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20 536 people, BMJ 2006 doi:10.1136/bmj.38993.731725.BE(published 10 November 2006)
  6. Cholesterol Treatment Trialists’ (CTT) Collaborators, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet 2012; 380: 581–590
  7. Arzneimittelkomission der Deutschen Ärzteschaft. Arzneiverordnungen in der Praxis (AVP) 2012, Therapieempfehlungen Fettstoffwechselstörungen
  8. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies, European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) European Heart Journal (2012) 33, 1635–1701
  9. Shepherd J. Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs. Lancet 2002; 359: 2271–2273PubMedView Article
  10. Cholesterol Treatment Trialists’ (CTT) Collaboration, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials, Lancet 2010; 376: 1670–1681View Article
  11. Egan A et al. Weighing the Benefits of High-Dose Simvastatin against the Risk of Myopathy, N Engl J Med 2011; 365;4 285–286PubMedView Article
  12. Wei L et al. Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study Pharmacoepidemiol Drug Safety 2007; 16: 385–392
    1. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a metaanalysis of randomized controlled trials. JAMA 1999; 282: 2340–2346PubMedView Article
    2. Vrecer M, Turk S, Drinovec J, Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int J Clin Pharmacol Ther 2003; 41: 567–577PubMed
    3. Cheung BMY, Lauder IJ, Lau C-P, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004; 57: 640–651PubMedView Article
    4. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen,Nutzenbewertung der Statine unter besonderer Berücksichtigung von Atorvastatin (2005), https://​www.​iqwig.​de/​nutzenbewertung-der-statine-unter-besonderer.​986.​html?​tid=​1204
    5. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy. JACC 2006; 48: 438–445PubMed
    6. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
    7. Sacks FM, Pfeffer MA, Moye LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001–1009.PubMedView Article
    8. Shepherd J: The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am J Cardiol 1995; 76: 113C–117CPubMedView Article
    9. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326):7–22.
    10. Brown BG, Hillger L, Zhao XQ, Poulin D, Albers JJ: Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS trial. Familial Atherosclerosis Treatment Study. Ann N Y Acad Sci 1995; 748: 407–417PubMedView Article
    11. Schwartz GG, Olsson AG, Ezekowitz MD et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Jama 2001; 285: 1711–1718PubMedView Article
    12. Shepherd J. Resource management in prevention of coronary heart disease: optimizing prescription of lipid-lowering drugs. Lancet 2002; 359(9325):2271–2273PubMedView Article
Metadaten
Titel
Einfache Therapie fördert die Compliance
„Fire and forget“ statt „Treat to target“
verfasst von
Prof. Dr. med. Bernd Mühlbauer
Publikationsdatum
20.12.2012
Verlag
Urban and Vogel
Erschienen in
CardioVasc / Ausgabe 6/2012
Print ISSN: 1617-4933
Elektronische ISSN: 1618-3851
DOI
https://doi.org/10.1007/s15027-012-0333-7

Weitere Artikel der Ausgabe 6/2012

CardioVasc 6/2012 Zur Ausgabe

Interdisziplinäre Lipidsprechstunde

Eine gefährliche Kombination

Jahrestagung der American Heart Association (AHA) vom 3. bis 7. November 2012 in Los Angeles

Studien mit hohem Gebrauchswert

Jahrestagung der American Heart Association (AHA) vom 3. bis 7. November 2012 in Los Angeles

ICD: Fortschritt durch intelligente Programmierung

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.